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Cost-eﬀ ectiveness of two versus three or more doses of 
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pregnancy in sub-Saharan Africa: a modelling study of 
meta-analysis and cost data
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Feiko O ter Kuile, Kara Hanson
Summary
Background In 2012, WHO changed its recommendation for intermittent preventive treatment of malaria during 
pregnancy (IPTp) from two doses to monthly doses of sulfadoxine-pyrimethamine during the second and third trimesters, 
but noted the importance of a cost-eﬀ ectiveness analysis to lend support to the decision of policy makers. We therefore 
estimated the incremental cost-eﬀ ectiveness of IPTp with three or more (IPTp-SP3+) versus two doses of sulfadoxine-
pyrimethamine (IPTp-SP2).
Methods For this analysis, we used data from a 2013 meta-analysis of seven studies in sub-Saharan Africa. We developed 
a decision tree model with a lifetime horizon. We analysed the base case from a societal perspective. We did deterministic 
and probabilistic sensitivity analyses with appropriate parameter ranges and distributions for settings with low, moderate, 
and high background risk of low birthweight, and did a separate analysis for HIV-negative women. Parameters in the 
model were obtained for all countries included in the original meta-analysis. We did simulations in hypothetical cohorts 
of 1000 pregnant women receiving either IPTp-SP3+ or IPTp-SP2. We calculated disability-adjusted life-years (DALYs) for 
low birthweight, severe to moderate anaemia, and clinical malaria. We calculated cost estimates from data obtained in 
observational studies, exit surveys, and from public procurement databases. We give ﬁ nancial and economic costs in 
constant 2012 US$. The main outcome measure was the incremental cost per DALY averted.
Findings The delivery of IPTp-SP3+ to 1000 pregnant women averted 113·4 DALYs at an incremental cost of 
$825·67 producing an incremental cost-eﬀ ectiveness ratio (ICER) of $7·28 per DALY averted. The results remained 
robust in the deterministic sensitivity analysis. In the probabilistic sensitivity analyses, the ICER was $7·7 per DALY 
averted for moderate risk of low birthweight, $19·4 per DALY averted for low risk, and $4·0 per DALY averted for 
high risk. The ICER for HIV-negative women was $6·2 per DALY averted.
Interpretation Our ﬁ ndings lend strong support to the WHO guidelines that recommend a monthly dose of IPTp-SP 
from the second trimester onwards.
Funding Malaria in Pregnancy Consortium and the Bill & Melinda Gates Foundation.
Copyright © Fernandes et al. Open Access article distributed under the terms of CC BY-NC-SA.
Introduction
Malaria during pregnancy can lead to poor health 
outcomes in both mother and child.1 In 2007, 32 million 
pregnant women were at risk of malaria infection in 
sub-Saharan Africa.2 The prevention and consequences 
of diseases and their related treatments during pregnancy 
are generally complex from an epidemiological, public 
health, and economic perspective because both the 
mother and her unborn baby are often aﬀ ected. 
Plasmodium falciparum infection in pregnant women in 
sub-Saharan Africa is most importantly associated 
with maternal anaemia, perinatal mortality, and low 
birthweight caused by intrauterine growth restriction 
and prematurity, especially in women pregnant for the 
ﬁ rst or second time.1 At present, the control of malaria 
during pregnancy consists of intermittent preventive 
treat ment during pregnancy (IPTp) with sulfadoxine-
pyrimethamine, the provision of insecticide-treated 
bednets, and eﬀ ective case management of clinical 
malaria.3 Findings from several economic evaluations 
have shown that two doses of IPTp with sulfadoxine-
pyrimethamine (IPTp-SP) versus case management only 
or placebo is highly cost eﬀ ective.4–6 However, the 
emergence and spread of strains of P falciparum resistant 
to sulfadoxine-pyrimetha mine has led to rising concerns 
about the ongoing eﬀ ectiveness of IPTp-SP.7
After an expert meeting in June, 2012, WHO recom-
mended that all pregnant women, unless receiving 
co-trimoxazole prophylaxis, should receive IPT-SP 
monthly from their second trimester onwards.8,9 The 
clinical evidence behind this decision was provided 
in a meta-analysis by Kayentao and colleagues10 that 
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compared three or more doses versus two doses of 
IPTp-SP. Their ﬁ ndings suggested that receiving three or 
more doses (weighted mean of actual doses received was 
2·79) of IPTp-SP were associated with higher birthweight 
and a lower risk of low birthweight (relative risk=0·80, 
95% CI 0·69–0·94) than were two doses of IPTp-SP 
(weighted mean of actual doses received was 1·65). The 
results of the meta-analysis were consistent and did 
not show evidence for heterogeneity, despite studies 
being done in areas of varying levels of sulfadoxine-
pyrimethamine resistance.10
In addition to the epidemiological evidence, it is crucial 
for policy makers to understand the cost-eﬀ ectiveness 
and cost drivers of any new regimen.
We aimed to estimate the incremental cost-eﬀ ectiveness 
of IPTp-SP com paring three or more (SP3+) doses with 
two (SP2) doses. Our cost-eﬀ ectiveness model incorporated 
pri mary and secondary endpoints (low birthweight, 
anaemia, and maternal parasitaemia) in Kayentao and 
colleagues’ meta-analysis.10
Methods
Study design
Details of the study setting, population, and intervention 
for each trial included in this analysis are reported 
elsewhere.10 Kayentao and colleagues10 previously 
synthesised data from seven trials done in six countries 
(Burkina Faso, Kenya, Malawi [two trials], Mali, Tanzania, 
and Zambia). Four studies included all pregnant women 
irrespective of the number of pregnancies they had had, 
whereas recruitment for the remaining three was 
restricted to women who were pregnant for the ﬁ rst or 
second time only. Four studies included women with or 
without HIV, the study in Zambia included only those 
with HIV, and the two west African trials did not screen 
for HIV status. The malaria transmission settings 
were either holoendemic (ﬁ ve trials) or hyperendemic 
(two trials). The trials were done between 1994 and 2008, 
with six taking place between 2002 and 2008. The 
average age of women enrolled in the trials was 
22·8 years, excluding the Tanzanian trial for which data 
were unavailable.10
Eﬀ ects
4345 (69%) of 6281 women in the meta-analysis were 
pregnant for either the ﬁ rst or second time, a proportion 
higher than that occurring in the general population in 
the six countries.11–16 We therefore used the baseline 
risks and measures of eﬀ ects stratiﬁ ed by gravidity 
listed by Kayentao and colleagues.10 We considered for 
inclusion in the model only statistically signiﬁ cant 
outcomes (p value ≤0·05) in either of the gravidae 
subgroup results. Data for clinical malaria were not 
available so, as a surrogate measure, we used maternal 
peripheral parasitaemia multiplied by the proportion of 
pregnant women with parasitaemia who had 
documented fever in high to medium transmission 
areas (7%; 107 of 1563).17 There was no diﬀ erence in the 
risk of serious adverse events between the SP3+ and 
SP2 group. Additionally, evidence from large-scale 
passive surveillance in Blantyre District, Malawi, 
suggests that adverse reactions to sulfadoxine-
pyrimethamine (eg, Steven-Johnson syndrome) were 
rare (1·7 cases per 100 000 exposures in adults).18
The ﬁ nal cost-eﬀ ectiveness model included low 
birthweight, moderate to severe maternal anaemia 
(haemoglobin <80 g/L, 70 g/L, or 60 g/L), and clinical 
malaria as outcomes. The relative risks were estimated 
with random eﬀ ects log binomial regression models as 
described by Kayentao and colleagues.10 We used the 
median baseline risk in the SP2 group and the relative 
risk for each outcome of interest to calculate the 
intervention-group risk. Outcomes were not strat iﬁ ed 
by HIV status, but the cost-eﬀ ectiveness of IPTp-
SP3+ for HIV-negative women was explored in a 
sensi tivity analysis.
Costs
We included the variable cost to the health provider and 
household in the model, but excluded the ﬁ xed costs 
such as training, dissemination or policy change of 
extending an existing intervention to a higher frequency 
of dosing, because they were regarded as negligible. We 
excluded cost savings due to averting clinical outcomes 
from this analysis because data were not available. We 
calculated economic costs (including indirect cost of 
time spent travelling to and waiting at the health 
Figure 1: The decision tree
The decision tree model shows the example for LBW. All numbers are the results published by Kayentao and 
colleagues.10 The example shown here is representative of a setting with moderate LBW risk and included all 
pregnant women independent of HIV status (positive, negative, unknown). The same structure was used for 
severe anaemia and clinical malaria. LBW=low birthweight. IPTp-SP=intermittent preventive treatment with 
sulfadoxine-pyrimethamine. SP2=two doses of IPTp-SP  during pregnancy. SP3+=three or more doses of IPTp-SP 
during pregnancy. G1/G2=women who have had one or two pregnancies. G3+=women who have had three or 
more pregnancies. 
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facility) and ﬁ nancial costs and expressed them in 
constant 2012 US$ by using the local consumer price 
index19 and average 2012 exchange rates.20 All cost data 
collection was approved by the Institutional Review 
Board of the London School of Hygiene & Tropical 
Medicine and by the institution or country in which the 
data were collected.
The health provider costs comprise the cost of 
sulfadoxine-pyrimethamine and the value of nurses’ 
time to administer IPTp-SP. For details about how costs 
were estimated, see the appendix. Household costs 
included the direct (transport) and indirect (value of 
time spent travelling to and waiting at the health facility) 
costs of women attending antenatal care at least 
three times during the second and third trimester versus 
twice, and the arbitrary assumption was made that 25% 
of the costs (direct and indirect) of these visits were 
attributed to IPTp-SP (varied to 0% and 100% in 
deterministic sensitivity analysis; appendix).
Statistical analysis and modelling
We adopted a societal perspective (which takes into account 
the cost of the intervention to the health provider but also 
the additional cost to the recipient of the intervention) 
because attendance at antenatal care is inadequate in many 
settings and therefore the cost to households of increasing 
the number of visits could be substantial. We developed 
separate but structurally identical decision tree models 
(ﬁ gure 1) with a lifetime horizon for each outcome because 
data for concurrence of outcomes were un available. To 
model the cost-eﬀ ectiveness in a population with a 
gravidity distribution representative of the six countries, 
Base New value (% 
change compared 
with base case)
Incremental 
cost
Incremental 
DALYs
Incremental 
cost-eﬀ ective-
ness ratio
% change
Base case NA NA 825·7 113·4 7·3 NA
Simultaneously change relative risk: all outcomes (all gravidae), lower value NA All low 825·7 225·6 3·7 –49·7%
Simultaneously change relative risk: all outcomes (all gravidae), higher value NA All high 825·7 15·4 53·7 637·1%
Simultaneously change relative risk: low birthweight (all gravidae), lower value NA All low 825·7 223·3 3·7 –49·2%
Simultaneously change relative risk: low birthweight (all gravidae), higher value NA All high 825·7 16·3 50·7 595·7%
Low and high background risk of low birthweight (G1/G2 and G3+), lower value NA All low 825·7 45·8 18·0 147·5%
Low and high background risk of low birthweight (G1/G2 and G3+), higher value NA All high 825·7 218·3 3·8 –48·0%
Increase antenatal care visits and IPTp-SP doses in SP3+ group 2·79 4·0 1585·1 113·7 14·0 92·0%
Relative risk low birthweight G3+ 95% CI, lower value 0·79 0·49 (–38·0%) 825·7 186·6 4·4 –39·2%
Relative risk low birthweight G3+ 95% CI, higher value 0·79 1·00 (26·6%) 825·7 62·2 13·3 82·3%
Nurses monthly cost of labour: min and max meta-analysis countries , lower value 542·76 101·93 (–81·2%) 427·9 113·4 3·8 –48·2%
Nurses monthly cost of labour: min and max meta-analysis countries, higher value 542·76 1243·30 (129·1%) 1457·8 113·4 12·9 76·6%
Relative risk low birthweight G1/G2 95% CI, lower value 0·80 0·68 (–15·0%) 825·7 150·1 5·5 –24·5%
Relative risk low birthweight G1/G2 95% CI, higher value 0·80 0·95 (18·8%) 825·7 67·5 12·2 68·0%
Discount rate, lower value 0·03 0·00 (–100·0%) 825·7 239·0 3·5 –52·5%
Discount rate , higher value 0·03 0·05 (66·7%) 825·7 78·0 10·6 45·3%
Disability weight low birthweight , lower value 0·11 0·05 (–50·0%) 825·7 79·4 10·4 42·8%
Disability weight low birthweight, higher value 0·11 0·16 (50·0%) 825·7 147·4 5·6 –23·1%
Sulfadoxine-pyrimethamine drug price, lower value 0·20 0·10 (–50·0%) 709·2 113·4 6·3 –14·1%
Sulfadoxine-pyrimethamine drug price, higher value 0·20 0·41 (100·0%) 1058·6 113·4 9·3 28·2%
Low birthweight attributable mortality risk, lower value 6·9% 3·5% (–50·0%) 825·7 91·2 9·1 24·4%
Low birthweight attributable mortality risk, higher value 6·9% 10·4% (50·0%) 825·7 157·8 5·2 –28·2%
Average health-care worker time per administration of sulfadoxine-pyrimethamine 95% CI, 
lower value
8·31 6·59 (–20·7%) 724·4 113·4 6·4 –12·3%
Average health-care worker time per administration of sulfadoxine-pyrimethamine 
95% CI, higher value
8·31 10·03 (20·7%) 927·0 113·4 8·2 12·3%
Percentage of household costs attributed to intermittent preventive treatment, lower value 25% 0% (–100·0%) 722·7 113·4 6·4 –12·5%
Percentage of household costs attributed to intermittent preventive treatment, higher value 25% 100% (300·0%) 1134·6 113·4 10·0 37·4%
Changes to structural model assumptions
Intervention delivered to primigravidae and secundigravidae only NA NA 825·7 178·4 4·6 –36·4%
HIV-negative only NA NA 825·7 139·0 5·9 –18·4%
Health provider perspective NA NA 722·7 113·4 6·4 –12·5%
Direct cost only NA NA 752·4 113·4 6·6 –8·9%
DALY=disability-adjusted life year. NA=not applicable. 
Table 1: Deterministic sensitivity analysis—parameter inputs and results
See Online for appendix
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each arm was stratiﬁ ed into women pregnant for the ﬁ rst 
or second time (G1/G2) and those pregnant for the third or 
more time (G3+). Subsequently we modelled the eﬃ  cacy 
of the intervention in a population with the gravidity 
distribution (G1/G2 vs G3+) as found in the most recent 
Demographic and Health Survey from the six countries.11–16
We calculated disability-adjusted life-years (DALYs) 
averted in each arm for each outcome separately and in 
total. When available, we used disability weights from the 
2010 Global Burden of Disease (GBD) study; otherwise 
we used 2004 GBD study estimates.21,22 We calculated 
DALYs with a 3% discount rate,23 as per conventional 
practice, with no age weighting (appendix). We calculated 
the incremental cost-eﬀ ectiveness ratio for a hypothetical 
cohort of 1000 women by dividing the incremental cost of 
the intervention by the incremental DALYs averted.
In the deterministic sensitivity analysis, we varied key 
variables and model assumptions to assess their relative 
contributions to uncertainty (table 1, ﬁ gure 2). The 
95% CI for all relative risk estimates in the G3+ 
subgroup included the value one.10 However, because no 
epidemiological evidence exists to suggest that more 
doses of IPTp-SP could result in higher numbers of low 
birthweight, severe anaemia, or maternal malaria cases, 
we capped the upper estimates of relative risks at 1·00 in 
the deterministic sensitivity analysis.
To gauge the robustness and uncertainty of all estimates 
and assumptions simultaneously, we did a probabilistic 
sensitivity analysis (ie, Monte Carlo simulation) using 
10 000 iterations, producing a point estimate and 95% CIs 
for the diﬀ erence in eﬀ ects and costs based on percentiles 
and an average incremental cost-eﬀ ectiveness ratio. In the 
probabilistic sensitivity analyses, we used all value ranges 
as reported in the meta-analysis so it would explicitly 
reﬂ ect the results published by Kayentao and colleagues, 
representative of a setting with moderate risk of low 
birthweight. We used commonly used cost-eﬀ ectiveness 
guidelines to assign an appropriate distribution to each 
parameter.24 Finally, we calculated the probability of 
IPTp-SP3+ being cost eﬀ ective for three frequently applied 
policymaker willingness-to-pay thresholds and plotted our 
results in a cost-eﬀ ectiveness acceptability curve.25 We 
refer to these thresholds as low (US$39·72), middle 
(US$238·33), and high (US$756·09; appendix).
We repeated the probabilistic sensitivity analyses 
described above for settings with a low or high 
low-birthweight risk by imputing the minimum (for low 
risk) or maximum (for high risk) value of the baseline 
risk range of low birthweight in both subgroups as 
presented by Kayentao and colleagues in place of the 
assumed control group risk (baseline risk in the SP2 
group, representative of a setting with moderate risk).
IPTp-SP is contraindicated for women receiving 
cotrimoxazole prophylaxis.26 We therefore also did a 
probabilistic sensitivity analysis for HIV-negative women. 
We changed baseline risks and relative risks for all 
outcomes and subgroups to those reported by Kayentao 
and colleagues for HIV-negative women.
We used STATA (version 12.0) for analysis of obser-
vational, exit survey, and Demographic and Health 
Survey data. We used Microsoft Excel 2013 for the 
decision tree model in the probabilistic sensitivity 
analysis using Visual Basic for Applications.
Role of the funding source
The funding institution had no role in the model 
design and development, data collection, analysis and 
inter pretation, or preparation, review, or approval of 
the paper. SF and ES had full access to all data in the 
model and take full responsibility for integrity of the 
Figure 2: Tornado diagram—deterministic sensitivity analysis
The variable ranges imputed for each variable are shown in parentheses. The light green bars show the direction and magnitude of change in the incremental 
cost-eﬀ ectiveness ratio, when the input variable is set to its minimum value; the dark green bars show the direction and magnitude of change when the input variable is 
set to its maximum. See appendix for more information. ANC=antenatal care. DALY=disability-adjusted life-years. G1/G2=Women who have had one or two pregnancies. 
G3+=women who have had three or more pregnancies. IPTp-SP=intermittent preventive treatment with sulfadoxine-pyrimethamine. SP=sulfadoxine-pyrimethamine. 
SP2=two doses of IPTp-SP during pregnancy. SP3+=three or more doses of IPTp-SP during pregnancy. *Relative risk capped at one, see methods and appendix..
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 Base case (low,high) Distribution for probabilistic 
sensitivity analysis
Source
Cost estimates
Health-care worker time cost
Health-care worker time per IPTp-SP administration (min; 95% CI) 8·31 (6·59–10·03) Gamma Observational studies (Ghana, Kenya, Malawi)*
Number of doses in SP2 group 1·65 Point estimate Kayentao et al (2013)10
Number of doses in SP3+ group 2·79 Point estimate Kayentao et al (2013)10
Nurses’ monthly cost of labour (US$2012; 95% CI) 542·76 (373·94–711·58) Gamma Ministry of Health data†
Drug cost
Average SP price per administration (US$2012; 95% CI) 0·20 (0·19–0·22) Lognormal International procurement databases‡
Household cost
Antenatal care visit direct cost (US$2012; 95% CI) 0·47 (0·42–0·53) Gamma Exit surveys Mali (N=778, Kenya=613)
Antenatal care visit indirect cost (US$2012; 95% CI) 1·17 (1·13–1·21) Gamma Exit surveys Mali (N=778, Kenya=613)
DHS data analysis
Percentage women in DHS with 0 antenatal care visits (95% CI) 8·40 (8·15–8·65) Dirichlet DHS meta-analysis countries§
Percentage of women in DHS with one antenatal care visit (95% CI) 3·90 (3·72–4·07) Dirichlet DHS meta-analysis countries§
Percentage of women in DHS with two ANC visits (95% CI) 12·78 (12·48–13·09) Dirichlet DHS meta-analysis countries§
Percentage of women in DHS with three or more antenatal care visits 
(95% CI)
74·92 (74·53–75·32) Dirichlet DHS meta-analysis countries§
Proportion G1/G2 women in meta-analysis countries (95% CI) 35·10 (34·05–36·14) Beta DHS meta-analysis countries§
DALY calculations
Discount rate r (range) 0·03 (0·00–0·05) Point estimate Assumption
Average age (years) 22·83 Point estimate Kayentao et al (2013)¶,10
Life expectancy for women aged 20–24 years (95% CI) 47·24 (41·79–51·51) Lognormal Wang et al (2010)||,27
Life expectancy at birth (95% CI) 57·96 (52·91–64·80) Lognormal Wang et al (2010)||,27
Length disability: malaria during pregnancy (3·5 days; range 2–6) 0·010 (0·005–0·016) Gamma Assumption
Length disability: malaria-related anaemia (21 days; range 14–42) 0·06 (0·04–0·12) Gamma Price et al (2001)28
Length disability: low birthwieght (95% CI) 57·96 (52·91–64·80) Lognormal Wang et al (2010)27
Disability weight infectious disease: severe acute episode (95% CI) 0·21 (0·14–0·30) Lognormal Salomon (2010)21
Disability weight maternal anaemia: moderate (95% CI) 0·06 (0·04–0·09) Lognormal Salomon et al (2010)21
Disability weight low birthweight 0·11 Point estimate World Health Organization22
Mortality estimates
Low birthweight attributable neonatal mortality risk (95% CI) 6·93% (4·36–9·50) Beta Marchant et al (2012)29
Case fatality rate: malaria during pregnancy (95% CI) 0·33% (0·26–0·45) Beta Sicuri et al (2010)5
Case fatality rate: moderate to severe anaemia in pregnancy 1·0% Beta Brabin el al (2001)30
Measures of eﬀ ect: primary and secondary endpoints used in model
Low birthweight
G1/G2: ACR per 1000 pregnant women (range) 181·00 (51·00–231·00) Point estimate** Kayentao et al (2013)10
G1/G2: relative risk (95% CI) 0·80 (0·68–0·95) Lognormal Kayentao et al (2013)10
G3+: ACR per 1000 pregnant women (range) 78·00 (42·00–212·00) Point estimate** Kayentao et al (2013)10
G3+: Relative risk (95% CI) 0·79 (0·49–1·27††) Lognormal Kayentao et al (2013)10
Moderate to severe maternal anaemia (<80 g/L,<70 g/L, or <60 g/L)
G1/G2: ACR per 1000 pregnant women (range) 36·00 (0·00–65·00) Point estimate** Kayentao et al (2013)10
G1/G2: relative risk (95% CI) 0·60 (0·36–0·99) Lognormal Kayentao et al (2013)10
G3+: ACR per 1000 pregnant women (range) 14·00 (0·00–63·00) Point estimate** Kayentao et al (2013)10
G3+: relative risk (95% CI) 1·18 (0·56–2·48††) Lognormal Kayentao et al (2013)10
Maternal parasitaemia
G1/G2: ACR per 1000 pregnant women (range) 130·00 (20·00–359·00) Point estimate** Kayentao et al (2013)10
G1/G2: relative risk (95% CI) 0·54 (0·37–0·80) Lognormal Kayentao et al (2013)10
G3+: ACR per 1000 pregnant women (range) 31·00 (00·00–263·00) Point estimate** Kayentao et al (2013)10
G3+: relative risk (95% CI) 0·97 (0·75–1·24††) Lognormal Kayentao et al (2013)10
Proportion of parasitaemic pregnant women with documented fever 
(%; 95% CI)
0·07 (0·03–0·38) Beta Van Eijk and colleagues‡‡,17
(Table 2 continues on next page)
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data and the model as well as accuracy of all analyses. 
SF had ﬁ nal responsibility for the decision to submit 
for publication.
Results
We estimated a total of 555·7 DALYs per 1000 women in 
the SP2 group and 442·3 DALYs per 1000 women in the 
SP3+ group. The total number of DALYs averted per 
1000 women amounted to 113·4, of which 112·4 (99·1%) 
can be attributed to low birthweight, 0·9 (0·8%) to severe 
anaemia, and 0·1 (0·1%) to clinical malaria in the mother.
Table 2 shows the average time to give one dose of 
IPTp-SP and the average monthly nurses’ labour. We 
estimated the total health provider cost of giving one dose 
of IPTp-SP as US$0·63, of which $0·43 (68·3%) was the 
cost of nurses’ time and $0·20 (31·7%) the cost of the drug.
Table 2 shows the direct cost of transport and indirect 
cost of time to the household, giving a total household 
cost of $1·64 per antenatal care visit of which $0·41 (25%) 
was attributed to IPTp-SP. The antenatal care attendance 
of women in the six countries was high, with 74·9% 
attending three or more times, 12·8% twice, 3·9% once, 
and 8·4% never (table 2).
The total economic cost of providing treatment to 
1000 women was $1948·64 for IPTp-SP3+ and $1122·97 
for IPTp-SP2, giving an incremental cost of $825·67 per 
1000 women. $102·99 (12·5%) of the total incremental 
cost in the base case was the household cost of IPTp-SP, 
and the remaining $722·68 (87·5%) was the health 
provider cost. Total incremental ﬁ nancial cost was 
$752·38 per 1000 women.
The cost of delivering IPTp-SP3+ to 1000 pregnant 
women in the base case scenario (table 2) gives an 
incremental cost-eﬀ ectiveness ratio of $7·28 per DALY 
averted. For the deterministic sensitivity analysis, 
ﬁ gure 2 and table 1 show the results and percentage 
change for changes in parameter inputs, changes to 
methodological assumptions, or subgroup analysis in 
which the variation resulted in at least 5% change in the 
incre mental cost-eﬀ ectiveness ratio. The base case incre-
mental cost-eﬀ ectiveness ratio was substantially below 
the low willingness-to-pay threshold of $39·72 per DALY 
averted. Although some variations in the deterministic 
sensitivity analysis resulted in substantial percentage 
changes in the incremental cost-eﬀ ectiveness ratio, only 
two relatively radical changes (in which relative risks for 
all outcomes and subgroups were varied to the upper 
limit of the 95% CI reported) increased the ratio beyond 
the low willingness-to-pay threshold of $39·72 and none 
of them resulted in a change beyond the middle 
willingness-to-pay threshold of $238·33.
The probabilistic sensitivity analyses for settings with a 
moderate risk of low birthweight (ﬁ gure 3A) resulted in 
an incremental cost of $825·18 (95% CI 299·74–2541·85) 
 Base case Distribution for probabilistic 
sensitivity analysis
Source
(Continued from previous page)
Secondary endpoints (not used in model)§§
Placental malaria ACR per 1000 women (all gravidae; range) 63·00 (00·00–256·00) Point estimate** Kayentao et al (2013)10
Placental malaria relative risk (all gravidae; 95% CI) 0·51 (0·38–0·68) Lognormal Kayentao et al (2013)10
Secondary endpoints (not statistically signiﬁ cant, only relative risk shown; for information only, not used in model)¶¶
Preterm delivery relative risk (G1/G2; 95% CI) 0·95 (0·81–1·11) ·· Kayentao et al (2013)10
Preterm delivery relative risk (G3+; 95% CI) 0·85 (0·56–1·27) ·· Kayentao et al (2013)10
Miscarriage relative risk (G1/G2; 95% CI) 1·75 (0·97–3·13) ·· Kayentao et al (2013)10
Miscarriage relative risk (G3+; 95% CI) 0·90 (0·37–2·19) ·· Kayentao et al (2013)10
Stillbirth relative risk (G1/G2; 95% CI) 1·14 (0·79–1·65) ·· Kayentao et al (2013)10
Stillbirth relative risk (G3+; 95% CI) 1·24 (0·61–2·50) ·· Kayentao et al (2013)10
Neonatal death relative risk (G1/G2; 95% CI) 0·74 (0·45–1·24) ·· Kayentao et al (2013)10
Neonatal death relative risk (G3+; 95% CI) 1·31 (0·59–2·93) ·· Kayentao et al (2013)10
Parameters are shown for all countries included in the meta-analysis by Kayentao and colleagues’ meta-analysis:10 Burkina Faso, Malawi, Mali, Kenya, Tanzania, Zambia. ACR=assumed control group risk. 
DALY=disability-adjusted life-years. DHS=Demographic and Health Survey. G1/G2=women in ﬁ rst or second pregnancy. G3+=women in third or more pregnancy. IPTp-SP=intermittent preventive treatment with 
sulfadoxine-pyrimethamine. SP2=two doses of IPTp-SP during pregnancy. SP3+=three or more doses of IPTp-SP during pregnancy. *Data for time needed to give one dose of IPTp-SP were obtained in 
observational studies in Ghana (n=18), Kenya (n=40) and Malawi (n=18); data from Ghana were the only data representative of a west African setting. †Salary scale and an average allowance package for nurses 
from Ministry of Health in Burkina Faso, Malawi, Mali, Kenya, Tanzania, and Zambia for 2012. ‡Cost per dose of IPTp-SP was calculated for three doses accounting for 5% wastage, 10% insurance and freight, and 
10% transport. §The most recent Demographic and Health Survey datasets were: Burkina Faso (2010), Kenya (2008–09), Malawi (2010), Mali (2006), Tanzania (2009–10), Zambia (2007). ¶Average age was 
calculated from all trials included in the meta-analysis by Kayentao and colleagues,10 except for the trial done in Tanzania because age data were not available to investigators. ||The life expectancy was analysed 
from the Global Burden of Disease 2010 database for the subgroups of interest (ie, women only, aged 20–24 years, meta-analysis countries and at birth, both sexes and meta-analysis countries, respectively). 
**The range shows the risk in low-risk and high-risk populations and will only be used in deterministic sensitivity analysis. ††We capped relative risk values in the deterministic sensitivity analysis at 1 because 
there is no evidence that suggests giving more doses of IPTp-SP could result in higher numbers of low birthweight, severe anaemia, or clinical malaria; in the probabilistic sensitivity analysis, distributions were 
assigned to the 95% CIs as reported by Kayentao and colleagues10 irrespective of them including 1·0). ‡‡Passive case detection in the control of malaria in pregnancy in low transmission areas in Africa; 
a meta-analysis of observational studies of the association between fever and malaria infection; unpublished data that were presented at conference. §§No data available to be able to use placental malaria as a 
proxy for clinical malaria, it was therefore not used in the model. ¶¶Endpoints that were not statistically signiﬁ cant in any of the subgroups (G1/G2 or G3+) were excluded from the model and are listed here. 
Table 2: Input variables for the base case and probabilistic cost-eﬀ ectiveness analysis
Articles
www.thelancet.com/lancetgh   Vol 3   March 2015 e149
and 106·56 incremental DALYs averted (95% CI–17·23 to 
201·71) per 1000 women. We estimated the average 
incremental cost-eﬀ ectiveness ratio at $7·74 per DALY 
averted (median 5·96).
The probabilistic sensitivity analyses results for 
settings with low and high low-birthweight risk are 
shown in ﬁ gures 3B and 3C. The average incremental 
cost-eﬀ ectiveness ratio was $19·41 per DALY (median 
13·87) averted for low-risk settings (incremental cost 
$819·00 [301·61–2482·48] and 42·20 incremental DALYs 
averted [–17·57 to 88·68]) and $3·99 per DALY averted 
(median 2·82) for high-risk settings (incremental cost 
$814·06 [299·01–2468·15] and 204·11 incremental 
DALYs averted [95% CI –107·29 to 425·63]). The 
simulations for setting with a low risk of low-birthweight 
were more densely concentrated around the median, 
with a higher proportion of points in the northwest 
quadrant of the cost-eﬀ ectiveness plane. For settings 
with a high risk of low birthweight the estimates were 
more widely distributed around the median in both 
directions, but the overall proportion of simulations 
falling into the northeast quadrant was higher than in 
moderate-risk and low-risk settings.
Figure 3D shows the results of probabilistic sensitivity 
analyses for HIV-negative women. We calculated the 
incremental cost at $821·28 (299·50–2549·81) and the 
incremental DALYs averted at 132·53 (15·87 to 231·89). 
The incremental cost-eﬀ ectiveness ratio was $6·20 per 
DALY averted (median 5·02). The simulations for 
HIV-negative women are more densely concentrated 
around the median in the northeast quadrant than 
in the probabilistic sensitivity analyses that included 
all women.
In ﬁ gure 4, the probability of IPTp-SP3+ being cost-
eﬀ ective is shown in a cost-eﬀ ectiveness acceptability 
curve for willingness-to-pay values up to $800 per 
DALY averted. The probability of IPTp-SP3+ falling 
below the highly attractive threshold of $39·72 and 
hence being highly cost-eﬀ ective was 92·4% for 
moderate risk of low birthweight, 78·1% for low risk of 
low birthweight, and 90·4% for high risk of low 
birthweight, and 96·6% for HIV-negative women.
Figure 3: Cost-eﬀ ectiveness planes
The graphs show the results of four diﬀ erent Monte Carlo Simulations with 10 000 iterations each using the value ranges and distributions speciﬁ ed in table 2. The assumed control group risk point 
estimates for low birthweight in both gravidae subgroups were varied in the three scenarios, representing cost-eﬀ ectiveness in moderate risk (A), low risk (B), and high risk (C) of low birthweight 
settings. Panel D shows the results for the simulation using input parameters reported for HIV-negative women by Kayentao and colleagues.10 For the moderate risk of low birthweight setting, we used 
the base case parameter values of the assumed control group risk reported by Kayentao and colleagues; for low-risk and high-risk groups we used the minimum and maximum value of the parameter 
range. All other values, ranges, and distributions were kept the same. WTP=willingness to pay. DALYs=disability-adjusted life-years. SP2=two doses of IPTp-SP. SP3+=three or more doses of IPTp-SP. 
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Discussion
Our ﬁ ndings suggest that, at just $7·28 per DALY averted, 
IPTp-SP3+ can be a highly cost-eﬀ ective intervention 
when incorporated into an existing antenatal care package. 
In settings with moderate malaria transmission, 
IPTp-SP3+ has a 92·4% probability of being highly 
cost-eﬀ ective using a threshold of $39·7 per DALY averted. 
It is substantially more cost-eﬀ ective than many health 
interventions recommended for imple mentation in 
sub-Saharan Africa (ie, rotavirus vaccination 
recommended at $43 per DALY averted or PMTCT at $37–
69 per DALY averted).27 Furthermore, our deterministic 
sensitivity analysis indicates that IPTp-SP3+ remains 
highly cost-eﬀ ective under a wide range of assumptions 
about key parameter values as well as structural 
assumptions. The incremental cost-eﬀ ectiveness ratio was 
more than the willingness-to-pay threshold of $39·7 in 
only two extreme cases. Finally, our modelling results in 
ﬁ gures 3 and 4 suggest that three or more doses of 
IPTp-SP would be highly cost eﬀ ective for settings with 
low to high baseline risk of low birthweight. IPTp-SP3+ 
for HIV-negative women has an even higher probability of 
being cost eﬀ ective (96·6%). Therefore, our ﬁ ndings not 
only lend support to the new WHO guidelines for 
IPTp-SP, with monthly dosing at each scheduled 
antenatal-care visit, but also show the cost-eﬀ ectiveness 
of IPTp-SP3+ irrespective of whether all women or only 
HIV-negative women are considered (panel).
In estimating costs, we deliberately used a conservative 
approach by including both incremental staﬀ  time needed 
to give the intervention and the incremental costs to 
women of additional antenatal-care visits. This means that 
the costs shown here are likely to overestimate the actual 
cost and therefore underestimate the cost-eﬀ ectiveness. 
Policy makers might take a more limited perspective on 
costs and therefore be interested in the results in the 
sensitivity analysis, which showed that, when only the 
costs to the health provider are considered, IPTp-SP3+ 
was even more cost eﬀ ective (table 1 and ﬁ gure 2). 
Furthermore, the incremental cost would be substantially 
reduced if it included cost savings due to a reduction in 
the number of babies born with low birthweight in 
particular, but also due to the number of cases of severe 
anaemia and clinical malaria averted. The probabilistic 
sensitivity analyses included the full range of the 95% CI 
reported for relative risks, even when these were not 
statistically signiﬁ cant and the range included one, 
implying that IPTp-SP2 could possibly be more eﬃ  cacious 
than IPTp-SP3+ in a particular gravidity subgroup. 
Provision of more doses of IPTp-SP is highly unlikely to 
result in more cases of low birthweight, severe anaemia, 
or clinical malaria. We nevertheless chose to include the 
full 95% CI range in the probabilistic sensitivity analyses 
so the analysis could reﬂ ect the results presented by 
Kayentao and colleagues.10 This choice explains the 
simulation points on the northwestern quadrant of the 
cost-eﬀ ectiveness plane (positive incremental costs and 
negative incremental DALYs) and the inclusion of zero in 
the 95% CI of the incremental DALYs averted.
Our model had several limitations. In their 
meta-analysis,10 Kayentao and colleagues pointed out 
some potential sources of bias, which could have led to 
the overestimation of the eﬀ ectiveness of IPTp-SP3+, 
including the fact that only one of the seven trials was 
placebo-controlled; and the meta-analysis results could 
not be stratiﬁ ed by bednet use. Because of the 
unavailability of information about concurrence of 
outcomes, we were unable to construct one decision 
tree model for all three outcomes, but had to sum up 
our results from three independent decision tree 
models. Although not ideal, this is unlikely to have had 
an eﬀ ect on our results because the largest proportion 
Figure 4: Cost-eﬀ ectiveness acceptability curves
The curves show the probability of three doses of intermittent preventive treatment with sulfadoxine-pyrimethamine 
being cost eﬀ ective at any given willingness-to-pay (WTP) value for moderate (A), and low and high (B) low 
birthweight risk settings as well as for HIV-negative women only. The vertical lines indicate three WTP thresholds. 
BF=Burkina Faso. DALY=disability adjusted life year. GDP=gross domestic product. ML=Mali. MW=Malawi. KE=Kenya. 
TZ=Tanzania. WHO=World Health Organization. ZM=Zambia. CE=cost eﬀ ective.
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(99·4%) of the DALYs averted originated from the 
low-birthweight cases averted and therefore the 
likelihood of double counting aﬀ ecting the ﬁ nal results 
is minimal. Data for the number of episodes of clinical 
malaria during pregnancy were not available from the 
meta-analysis because these were rarely reported in the 
source trials; therefore we approximated this parameter 
by multiplying the risk of maternal parasitaemia by 
the average proportion of pregnant women with 
parasitaemia who had documented fever (6·8%) 
obtained from another meta-analysis.17 Although not 
ideal, this approximation is unlikely to have aﬀ ected the 
cost-eﬀ ectiveness substantially because our surrogate 
measure of clinical malaria contributed less than 0·5% 
to the total DALYs averted.
A further limitation is that we calculated the hypo-
thetical cost to the household of 100% coverage of 
antenatal care with at least two visits for the IPTp-SP2 
arm and of at least three visits for the IPTp-SP3+ arm, 
translating into one incremental visit for all women 
attending care up to two times. However, we are aware 
that the potential cost of attending antenatal care might 
be much higher for women who never attend antenatal 
care, and the cost to the health provider of encouraging 
those women is unknown. Our model is based on the 
assumption that, on average, 2·8 doses were given in the 
IPTp-SP3+ groups and 1·6 doses were given in the 
IPTp-SP2 group. We acknowledge that monthly IPTp as 
recommended by WHO (if the average number of visits 
per woman exceed 2·8 visits) would result in higher 
costs, and the incremental eﬃ  cacy of adding more doses 
of IPTp is unknown. However, we showed in the 
sensitivity analysis that increasing the costs based on an 
average of four antenatal care visits in the IPTp-SP3+ 
group increased the incremental cost-eﬀ ectiveness ratio 
to $13·98 per DALY averted and IPTp-SP3+ remained 
highly cost eﬀ ective.
Although IPTp-SP3+ is very likely to be highly cost 
eﬀ ective, implementation of this new policy will present 
challenges. The proportion of women who received at 
least two doses of IPTp-SP is well below 60%32 in most 
countries, which is in contrast with high antenatal care 
attendance in many countries (average number of visits 
in the six countries was 3·3). The reasons for low IPTp 
coverage seem to be diverse and include drug stockouts 
and unclear messages given to health providers about 
IPTp, especially about timing of the dose.32 The 
introduction of IPTp-SP3+ could simplify the message 
to health professionals because it has to be given 
monthly at each scheduled visit, except during the ﬁ rst 
trimester. WHO has also recorded a “declining eﬀ ort to 
scale-up IPTp in a number of countries”.8 To reverse this 
trend and ensure access and uptake of IPTp-SP in these 
settings, substantial eﬀ orts are needed for the beneﬁ ts 
of monthly IPTp-SP to be realised. In other settings, 
such as Mali, average attendance is much lower, with 
2·6 visits per woman and 30·2% never attending 
antenatal care.12 In such settings, additional eﬀ orts are 
needed to encourage women to attend care earlier and 
more frequently. The household and provider costs of 
this attendance would need to be added to those of 
simply providing an additional intervention within an 
existing visit, and would reduce the cost-eﬀ ectiveness of 
the intervention.
The diminishing eﬀ ort in implementing IPTp-SP 
could partly be driven by health providers’ awareness of 
the increase in sulfadoxine-pyrimethamine resistance, 
particularly in eastern and southern Africa, the decrease 
in malaria transmission,33 and the hope for a new 
intervention to replace IPTp-SP soon. Although 
sulfadoxine-pyrimethamine resistance and malaria 
transmission intensity are heterogeneous across Africa, 
the results of the meta-analysis are consistent and do 
not show evidence for heterogeneity by resistance or 
endemicity level despite being done in areas with both 
low and high sulfadoxine-pyrimethamine resistance 
and intense perennial and highly seasonal transmission. 
However, all seven trials included in the meta-analysis 
were done in areas with either holoendemic malaria, 
where transmission is intense and occurs all year long, 
or in hyperendemic areas, with intense but highly 
seasonal transmission and periods of no malaria 
transmission during the dry season.10 Therefore, our 
ﬁ ndings may not be representative of other parts of 
Africa with less intense transmission and where the 
relative contribution of malaria to low birthweight 
might be smaller. Nevertheless, we hypothesise that 
women living in low transmission areas who might 
have lower levels of acquired immunity could beneﬁ t 
from the more frequent regimen as infections are more 
likely to result in symptomatic malaria and potentially 
preterm low birthweight.34,35
Panel: Research in context
Systematic Review
We did no systematic review for this cost-eﬀ ectiveness analysis. 
The baseline risks and measures of eﬀ ect used in our analysis 
were taken from a meta-analysis based on a systematic review 
published by Kayentao and colleagues in 2013.1 Other 
observational studies were either conducted by our own team, 
other people from the MiP consortium, or the literature was 
searched.
Interpretation
When provided as part of the existing antenatal care package, 
IPTp-SP3+ in combination with insecticide-treated bednets 
provides highly cost-eﬀ ective protection from malaria for 
pregnant women in most of sub-Saharan Africa. Care should be 
taken when extrapolating these ﬁ ndings to areas with low or 
unstable malaria transmission or areas with so-called super 
resistance (super resistant areas include three hot spots of 
resistance in northern Tanzania, western Kenya, and southern 
Uganda), which were not accounted for in our analysis. 
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Alternatively, in terms of sulfadoxine-pyrimethamine 
resistance levels, the consistency of the eﬀ ect estimates 
across the trials suggests that the results are 
generalisable within the limits of the resistance levels 
seen in the settings included in the studies, which are 
at present representative of more than 90% of 
sub-Saharan Africa.7 The notable exceptions are 
super-resistant areas, which are restricted to 
three hot-spots of resistance in northern Tanzania, 
western Kenya and southern Uganda, where data 
suggest that resistance undermines malaria control 
eﬀ orts in pregnant women. For a detailed discussion 
of the implications of sulfadoxine-pyrimethamine 
resistance for our results, see the appendix.
Despite the fear that sulfadoxine-pyrimethamine 
resistance can render IPTp-SP ineﬀ ective and the 
need for alternative drugs to replace sulfadoxine-
pyrimethamine or alternative strategies that use a more 
diagnostic-based test-and-treat intervention to replace 
IPTp with sulfadoxine-pyrimethamine in these areas, 
our ﬁ ndings show that IPTp-SP3+ in combination with 
insecticide-treated bednets provides highly cost-eﬀ ective 
protection from malaria for pregnant women in most of 
sub-Saharan Africa. This ﬁ nding stands irrespective of 
whether the intervention is given to all women, to 
women who have given birth once or twice, or to 
HIV-negative women only. The incremental 
cost-eﬀ ectiveness ratio was robust to changes in 
low-birthweight risk. Our ﬁ ndings therefore lend strong 
support to WHO guidelines that recommend a monthly 
dose of IPTp-SP from the second trimester onwards. 
Caution is needed, however, when extrapolating the 
ﬁ ndings to areas with low or unstable malaria 
transmission or areas with high drug resistance (such as 
the three hotspots listed above). Policy makers in a wide 
range of settings should therefore be conﬁ dent that 
changing to monthly sulfadoxine-pyrimethamine for 
IPTp will be a good use of their health budgets.
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